Targeting DHX9 Triggers Tumor-Intrinsic Interferon Response and Replication Stress in Small Cell Lung Cancer

Author:

Murayama Takahiko123ORCID,Nakayama Jun45ORCID,Jiang Xinpei1236ORCID,Miyata Kenichi78ORCID,Morris Alexander D.12ORCID,Cai Kathy Q.9ORCID,Prasad Rahul M.1ORCID,Ma Xueying123ORCID,Efimov Andrey10ORCID,Belani Neel11ORCID,Gerstein Emily R.12ORCID,Tan Yinfei12ORCID,Zhou Yan13ORCID,Kim William141516ORCID,Maruyama Reo717ORCID,Campbell Kerry S.123ORCID,Chen Lu12ORCID,Yang Yibin123ORCID,Balachandran Siddharth318ORCID,Cañadas Israel123ORCID

Affiliation:

1. 1Nuclear Dynamics and Cancer Program, Fox Chase Cancer Center, Philadelphia, Pennsylvania.

2. 2Cancer Epigenetics Institute, Fox Chase Cancer Center, Philadelphia, Pennsylvania.

3. 3Center for Immunology, Fox Chase Cancer Center, Philadelphia, Pennsylvania.

4. 4Laboratory of Integrative Oncology, National Cancer Center Research Institute, Tokyo, Japan.

5. 5Department of Oncogenesis and Growth Regulation, Research Institute, Osaka International Cancer Institute, Osaka, Japan.

6. 6Biomedical Science Graduate Program, Lewis Katz School of Medicine at Temple University, Philadelphia, Pennsylvania.

7. 7Project for Cancer Epigenomics, Cancer Institute, Japanese Foundation for Cancer Research, Tokyo, Japan.

8. 8Cancer Cell Communication Project, NEXT-Ganken Program, Japanese Foundation for Cancer Research, Tokyo, Japan.

9. 9Histopathology Facility, Fox Chase Cancer Center, Philadelphia, Pennsylvania.

10. 10Bio Imaging Facility, Fox Chase Cancer Center, Philadelphia, Pennsylvania.

11. 11Department of Medical Oncology, Fox Chase Cancer Center, Philadelphia, Pennsylvania.

12. 12Genomics Facility, Fox Chase Cancer Center, Philadelphia, Pennsylvania.

13. 13Biostatistics and Bioinformatics Facility, Fox Chase Cancer Center, Philadelphia, Pennsylvania.

14. 14Moores Cancer Center, UC San Diego, La Jolla, California.

15. 15Center for Novel Therapeutics, UC San Diego, La Jolla, California.

16. 16Department of Medicine, UC San Diego, La Jolla, California.

17. 17Cancer Cell Diversity Project, NEXT-Ganken Program, Japanese Foundation for Cancer Research, Tokyo, Japan.

18. 18Cancer Signaling and Microenvironment Program, Fox Chase Cancer Center, Philadelphia, Pennsylvania.

Abstract

Abstract Activating innate immunity in cancer cells through cytoplasmic nucleic acid sensing pathways, a phenomenon known as “viral mimicry,” has emerged as an effective strategy to convert immunologically “cold” tumors into “hot.” Through a curated CRISPR-based screen of RNA helicases, we identified DExD/H-box helicase 9 (DHX9) as a potent repressor of double-stranded RNA (dsRNA) in small cell lung cancers (SCLC). Depletion of DHX9 induced accumulation of cytoplasmic dsRNA and triggered tumor-intrinsic innate immunity. Intriguingly, ablating DHX9 also induced aberrant accumulation of R-loops, which resulted in an increase of DNA damage–derived cytoplasmic DNA and replication stress in SCLCs. In vivo, DHX9 deletion promoted a decrease in tumor growth while inducing a more immunogenic tumor microenvironment, invigorating responsiveness to immune-checkpoint blockade. These findings suggest that DHX9 is a crucial repressor of tumor-intrinsic innate immunity and replication stress, representing a promising target for SCLC and other “cold” tumors in which genomic instability contributes to pathology. Significance: One promising strategy to trigger an immune response within tumors and enhance immunotherapy efficacy is by inducing endogenous “virus-mimetic” nucleic acid accumulation. Here, we identify DHX9 as a viral-mimicry-inducing factor involved in the suppression of double-stranded RNAs and R-loops and propose DHX9 as a novel target to enhance antitumor immunity. See related commentary by Chiappinelli, p. 389. This article is featured in Selected Articles from This Issue, p. 384

Funder

G. Harold and Leila Y. Mathers Foundation

National Institute of General Medical Sciences

Lung Cancer Research Foundation

W. W. Smith Charitable Trust

Publisher

American Association for Cancer Research (AACR)

Cited by 13 articles. 订阅此论文施引文献 订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线,采集、加工和组织学术论文而形成的新型学术文献查询和分析系统,可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容,当前同舟云学术共收录了国内外主流学术期刊6万余种,收集的期刊论文及会议论文总量共计约1.5亿篇,并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询!咨询电话:010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号  京ICP备18003416号-3